Original Article

Modern Pathology (2015) 28, 1101–1122; doi:10.1038/modpathol.2015.77; published online 19 June 2015

Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)

W Glenn McCluggage1,15, Meagan J Judge2, Blaise A Clarke3, Ben Davidson4,5, C Blake Gilks6, Harry Hollema7, Jonathan A Ledermann8, Xavier Matias-Guiu9, Yoshiki Mikami10, Colin JR Stewart11,12, Russell Vang13 and Lynn Hirschowitz14,16

  1. 1Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK
  2. 2Royal College of Pathologists of Australasia, Sydney, NSW, Australia
  3. 3Department of Pathology and Laboratory Medicine, University Health Network, University of Toronto, Toronto, ON, Canada
  4. 4Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway
  5. 5Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
  6. 6Department of Pathology, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada
  7. 7Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
  8. 8Department of Oncology, UCL Cancer Institute, London, UK
  9. 9Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, Lleida, Spain
  10. 10Department of Diagnostic Pathology, Kumamoto University Hospital, Kumamoto, Japan
  11. 11Department of Histopathology, King Edward Memorial Hospital, Perth, WA, Australia
  12. 12School for Women's and Infant's Health, University of Western Australia, Crawley, WA, Australia
  13. 13Department of Pathology (Division of Gynecologic Pathology), The Johns Hopkins University School of Medicine, Baltimore, MD, USA
  14. 14Department of Cellular Pathology, Birmingham Women’s Hospital, Birmingham, UK

Correspondence: Professor WG McCluggage, FRCPath, Department of Pathology, Royal Group of Hospitals Trust, Grosvenor Road, Belfast BT12 6BA, Northern Ireland. E-mail: glenn.mccluggage@belfasttrust.hscni.net

15Chair of the ICCR Ovarian/Fallopian tube and Primary Peritoneal Site Cancer Panel.

16The ICCR Steering Group Representative.

Received 13 January 2015; Revised 24 February 2015; Accepted 25 February 2015
Advance online publication 19 June 2015

Top

Abstract

A comprehensive pathological report is essential for optimal patient management, cancer staging and prognostication. In many countries, proforma reports are used but these vary in their content. The International Collaboration on Cancer Reporting (ICCR) is an alliance formed by the Royal College of Pathologists of Australasia, the Royal College of Pathologists of the United Kingdom, the College of American Pathologists, the Canadian Partnership Against Cancer and the European Society of Pathology, with the aim of developing an evidence-based reporting data set for each cancer site. This will reduce the global burden of cancer data set development and reduplication of effort by different international institutions that commission, publish and maintain standardised cancer reporting data sets. The resultant standardisation of cancer reporting will benefit not only those countries directly involved in the collaboration but also others not in a position to develop their own data sets. We describe the development of a cancer data set by the ICCR expert panel for the reporting of primary ovarian, fallopian tube and peritoneal carcinoma and present the ‘required’ and ‘recommended’ elements to be included in the report with an explanatory commentary. This data set encompasses the recent International Federation of Obstetricians and Gynaecologists staging system for these neoplasms and the updated World Health Organisation Classification of Tumours of the Female Reproductive Organs. The data set also addresses issues about site assignment of the primary tumour in high-grade serous carcinomas and proposes a scoring system for the assessment of tumour response to neoadjuvant chemotherapy. The widespread implementation of this data set will facilitate consistent and accurate data collection, comparison of epidemiological and pathological parameters between different populations, facilitate research and hopefully will result in improved patient management.